Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Liquidia (LQDA)

Liquidia Q2 revenue rises to $8.8 million as net loss widens to $41.6 million

Mixed Impact 3 of 5 earnings Written later

Liquidia reported second quarter 2025 total revenue of $8.8 million, up from $3.7 million a year earlier, as YUTREPIA began commercial sales after FDA approval on May 23, 2025. The net loss widened to $41.6 million, or $0.49 per share, from $28.7 million, or $0.38 per share, as selling, general and administrative expenses rose to $38.8 million. Cash and cash equivalents were $173.4 million at June 30, 2025, and the filing includes no financial guidance.

Key points

  • Total revenue was $8.8 million versus $3.7 million a year earlier, including $6.5 million in YUTREPIA product sales.
  • Net loss was $41.6 million, or $0.49 per share, compared with $28.7 million, or $0.38 per share.
  • SG&A expenses were $38.8 million versus $19.9 million, including a $5.8 million rise in legal fees tied to YUTREPIA litigation.
  • As of August 8, specialty pharmacies reported more than 900 unique patient prescriptions and more than 550 patient starts.

The filing

CompanyLiquidia (LQDA)
Form8-K, current report
Filed with the SECAug 12, 2025, 6:30 AM ET
Accession number0001104659-25-076412

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:01 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.